UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | G | N | S
Number of items: 14.


Al-Azraqi, A; Angus, B; Gokul, S; Sinha, D; Calvert, AH; Lunec, J; (1999) Bcl-2 expression is a potential prognostic co-factor with P53-mutation status in epithelial ovarian carcinoma. British Journal of Cancer , 80 178 - ?.

Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, PJ; Endicott, JA; Gibson, AE; (1999) In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors. British Journal of Cancer , 80 110 - ?.


Batey, MA; Wright, JG; Simmonds, D; Proctor, M; Chapman, F; Fishwick, K; Azzabi, A; (1999) Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer. British Journal of Cancer , 80 259 - ?.


Calabrese, CR; Thomas, HD; Batey, MA; Boritzki, T; Zhang, K; White, AW; Curtin, NJ; (1999) Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research , 5 543 - ?.

Calvert, AH; Hughes, AN; Calvert, PM; Plummer, RE; Highley, MS; (1999) MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin. European Journal of Cancer , 35 1146 - ?.

Calvert, AH; Sessa, C; Hughes, A; Jochim, U; Calvert, P; Ghielmini, M; Renard, J; (1999) Pharmacokinetics (PK) of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies. European Journal of Cancer , 35 1147 - ?.

Calvert, H; (1999) MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Semin Oncol , 26 (2 Suppl 6) 105 - 108.

Calvert, PM; Highley, MS; Hughes, AN; Plummer, ER; Azzabi, AST; Verrill, MW; Camboni, MG; (1999) A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors. Clinical Cancer Research , 5 333 - ?.

Curtin, NJ; Kyle, S; Wang, LZ; Durkacz, BW; White, AJ; Srinivasan, S; Griffin, RJ; (1999) Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors. Clinical Cancer Research , 5 520 - ?.


Delaney, CA; Wang, LZ; Kyle, LZ; Srinivasan, S; White, AW; Curtin, NJ; Calvert, AH; (1999) Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines. British Journal of Cancer , 80 62 - ?.


Griffin, RJ; Barlow, HC; Curtin, NJ; Calvert, AH; Golding, BT; Newell, DR; Smith, PG; (1999) 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP). Clinical Cancer Research , 5 564 - ?.


Newell, DR; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, P; Endicott, JA; (1999) Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Clinical Cancer Research , 5 124 - ?.


Smith, PG; Barlow, HC; Loughlin, P; Huang, B; Bowman, KJ; Calvert, AH; Curtin, NJ; (1999) Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein. British Journal of Cancer , 80 82 - ?.

Smith, PG; Bewley, J; Gogel, JA; Calvert, AH; Newell, DR; Curtin, NJ; Chen, VJ; (1999) MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines. British Journal of Cancer , 80 83 - ?.

This list was generated on Sun Sep 25 04:01:58 2016 BST.